BioCentury | Jul 21, 2020
Product Development

Amplyx’s first-in-class antifungal heads for a head-to-head study

Following a positive Phase II readout, Amplyx plans to take lead candidate fosmanogepix into a Phase III head-to-head trial against echinocandins as first-line treatment for invasive Candida infections. Echinocandins are standard of care in the...
BioCentury | Jul 8, 2020
Finance

VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B

Investors in VarmX’s €32 million ($36.1 million) series B round brought together a deep-pocketed syndicate designed to support the Netherlands-based coagulation play through registrational studies for its lead program. INKEF Capital and Ysios Capital co-led...
BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

Aiming to develop precision cancer therapies that can treat more patients, Kinnate emerged from stealth Thursday with $74.5 million in an untranched series B from new investors OrbiMed Advisors, Nextech Invest and Vida Ventures. Foresite...
BioCentury | Jun 7, 2019
Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down. Over its 25-year...
BioCentury | Jul 13, 2018
Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BioCentury | Aug 4, 2017
Finance

Fungal flexibility

Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001. On Aug. 2, the biotech raised $67 million...
BioCentury | Nov 3, 2016
Company News

Signal, miRagen deal

miRagen will merge with Signal to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The...
BioCentury | Nov 1, 2016
Company News

miRagen finds public path via Signal merger

miRagen Therapeutics Inc. (Boulder, Colo.) will merge with Signal Genetics Inc. (NASDAQ:SGNL) to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain...
BioCentury | Oct 3, 2016
Finance

Guest Commentary: The generalist investor blame game

Peter Reikes, Vice Chairman, Stifel Nicolaus & Co., Ario Arabi, Associate, Stifel Nicolaus & Co. and Peter Nie, Analyst, Stifel Nicolaus & Co. Among the most popular explanations for the significant equity market moves in...
Items per page:
1 - 10 of 16
BioCentury | Jul 21, 2020
Product Development

Amplyx’s first-in-class antifungal heads for a head-to-head study

Following a positive Phase II readout, Amplyx plans to take lead candidate fosmanogepix into a Phase III head-to-head trial against echinocandins as first-line treatment for invasive Candida infections. Echinocandins are standard of care in the...
BioCentury | Jul 8, 2020
Finance

VarmX attracts investor syndicate with financial reserves to support coagulation company beyond €32M series B

Investors in VarmX’s €32 million ($36.1 million) series B round brought together a deep-pocketed syndicate designed to support the Netherlands-based coagulation play through registrational studies for its lead program. INKEF Capital and Ysios Capital co-led...
BioCentury | Dec 20, 2019
Financial News

Combining kinase biology with precision oncology, Kinnate raises $75M series B

Aiming to develop precision cancer therapies that can treat more patients, Kinnate emerged from stealth Thursday with $74.5 million in an untranched series B from new investors OrbiMed Advisors, Nextech Invest and Vida Ventures. Foresite...
BioCentury | Jun 7, 2019
Finance

Alexandria parlays growing life sciences real estate holdings into a flurry of VC deals

Alexandria has been leveraging its growing life sciences real estate revenues and relationships with leading VC firms to become the most prolific biotech investor, and it shows no signs of slowing down. Over its 25-year...
BioCentury | Jul 13, 2018
Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
BioCentury | Oct 6, 2017
Finance

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BioCentury | Aug 4, 2017
Finance

Fungal flexibility

Undisclosed first-in-human safety data persuaded a host of new investors to infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001. On Aug. 2, the biotech raised $67 million...
BioCentury | Nov 3, 2016
Company News

Signal, miRagen deal

miRagen will merge with Signal to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain miRagen's name and trade on NASDAQ. The...
BioCentury | Nov 1, 2016
Company News

miRagen finds public path via Signal merger

miRagen Therapeutics Inc. (Boulder, Colo.) will merge with Signal Genetics Inc. (NASDAQ:SGNL) to form a publicly traded microRNA company focused on hematological malignancies, pathological fibrosis and cardiovascular and neurodegenerative diseases. The surviving entity will retain...
BioCentury | Oct 3, 2016
Finance

Guest Commentary: The generalist investor blame game

Peter Reikes, Vice Chairman, Stifel Nicolaus & Co., Ario Arabi, Associate, Stifel Nicolaus & Co. and Peter Nie, Analyst, Stifel Nicolaus & Co. Among the most popular explanations for the significant equity market moves in...
Items per page:
1 - 10 of 16